+34 679 490 537info@nanbiosis.com

Posts Taged nanomedicine

Nanomedicine: how to get drugs to the place where they have to act.

At the beginning of June, the Jury of the Rei Jaume I 2018 Awards, formed by Nobel Prize winners, businessmen and scientists, met in Valencia to choose the winners.

Today has taken place the ceremony of delivery of the 30th edition of the awards presided over by King Felipe VI. Among the six winners, in the category of New Technologies was Ramón Martínez Mañez, Scientific Director of the CIBER-BBN and Unit 26 of NANBIOSIS.

Coinciding with its thirtieth anniversary, the Rei Jaume Foundation has produced a series of videos of interviews with the winners. In this video, Ramón Martínez Mañez, Scientific Director of Unit 26 of NANBIOSIS, who has received the Rei Jaume I Award for New Technologies, talks about the two major areas in which he works and other topics such as the recognition of science and the need to recover the talent of researchers who go out of Spain and a better connection between research and the company. Some of his answers are the following:

One of our lines of research is in the field of sensors: systems based on nanotechnology for the detection of substances such as the presence of pathogens that may be harmful to health. The other major area is nanomedicines for the controlled release of drugs, one of the fundamental ideas of nanomedicine is how to get drugs to the place where they have to act.

Recognition in science is obtained if your works are cited, having social recognition is much more difficult.

We are a good country in science but we are a country in the second division in the transfer of science to the companies, it is needed more investment so that the products end up coming to the market or so that more research is done in collaboration with companies in Spain.

It is good to leave Spain, not necessarily to succeed but to see how they work in other places. The problem that exists today is that it is very difficult to return to Spain and this is a pity because there are very well educated and very good people who stay abroad.

Read More

Ramón Martínez Máñez Master class on Nanomedicine at the Act of the Academic Opening year 2018-2019  of Spanish university

On September 25, the Polytechnic University of Valencia hosted the Solemn Act of the new Academic Opening year 2018-2019  of Spanish universities, coinciding with the commemoration of its 50th anniversary. This institutional act was chaired by S.M. King Felipe VI, the Minister of Science, Innovation and Universities, Pedro Duque, and the President of the Generalitat Valenciana, Ximo Puig, among many other authorities.

Ramón Martínez Máñez, has been in charge of teaching the master class of the new academic year. Ramón Martínez is professor of the Department of Chemistry of the UPV and director of the Interuniversity Research Institute of Molecular Recognition and Technological Development, besides Scientific Director of CIBER-BBN and Scientific Director of NANBIOSIS U26 NMR: Biomedical Applications II

In the master class, Martínez Máñez explained that nanomedicine aims to “identify diseases in their early stages at the cellular and molecular level through the use of nanodevices and contrast systems” in order to “provide an early diagnosis and, therefore, improve the prognosis of the disease“. Ramón Martínez Mañez, Rei Jaume I Award for New Technologies 2018 has underlined that, nanomedicine “is already a well-established area of ​​knowledge that seeks to apply the continuous advances of nanotechnology to medicine” and that “there are numerous studies that demonstrate its great capacity for the development of new diagnostic devices, new systems for the controlled release of drugs and materials suitable for the development of tissues.  In fact, as indicated “there are already in the market biomedical solutions based on nanotechnology such as nanoformulated drugs.” For the professor of the UPV, “we do not know what is the future of medicine, but without a doubt nanotechnology will play an important role in its development and, although we do not know who will carry out these advances, undoubtedly, the research developed in the university it will play a fundamental role “.

Read More

NANBIOSIS presented at the 12th annual event of the ETPN

During the days 17-19 of October Malaga has hosted the 12th annual event of European Platform of Technology in Nanomedicine (ETPN), a European meeting of 200 experts in research and innovation in nanomedicine.

The meeting was organized by Bionand, the Spanish Platform of Nanomedicine (Nanomed Spain), the Institute of Nanoscience of Madrid (Imdea) and the Center for Biomedical Research Network in the area of ​​Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), partner of NANBIOSIS.

During the event, the ETPN General Assembly took place as well as parallel meetings of the specialized working groups on different scientific and cross-cutting aspects related to nanomedicine

In this framework, the ICTS NANBIOSIS has been presented by the Scientific Director of CIBER-BBN, Ramón Martínez Máñez, to the European Nanomedicine community.

EUROPEAN TECHNICAL PLATFORM OF NANOMEDICINE

The European Technology Platforms are a key element in the European field of innovation, associations born with the mission of sharing knowledge, mobilizing the actors involved and developing sector strategies, all based on the social challenges established by the European Commission and with the ultimate goal of its translation to the market.

The European Nanomedicine Technology Platform (ETPN) was created in 2005 by the European Commission and a group of experts from academia and industry who have since contributed to the publication of various strategic documents identifying the needs and the roadmaps for research in Nanomedicine in Europe. Its main objectives are to establish a clear strategic vision of the sector, to reduce the fragmentation of nanomedical research, to mobilize public and private investment, to identify priority areas, to promote innovation in nanobiotechnologies for medical use and to strengthen Europe’s competitiveness in this sector scientific and industrial level

Currently, the ETPN has more than 120 members from 25 countries, representing all actors involved in nanomedicine, such as academic institutions, research centers, small and medium enterprises, industry, public agencies, representatives of the platforms the European Commission itself, among others.

Read More

NANOMEDICINE AND FUTURE, explained by Simó Schwartz, Director of U20 of NANBIOSIS.

NANBIOSIS-U20 Scientific Director, Simó Schwartz, speaks about Nanomedicine in an interview publish in http://www.quimicaysociedad.org.  NANBIOSIS is an Singular Scientific Technological Infrastructure (ICTS) that provides a complete service for the production and characterization of nanomaterials, biomaterials and systems in biomedicine, including the design and production of biomaterials and nanomaterials and their nanoconjugates, and the characterization of these bio-/nanomaterials, tissues and medicals devices from a physic-chemical, functional, toxicological and biological (including preclinical validation) point of view, focused also on biomedical applications such as: IVDs, biosensors, regenerative medicine, drug delivery, therapeutic agents or MRI contrast agents and medical devices.

Question: First of all, what is meant by nanomedicine?

Answer: Nanomedicine is considered any application of nanotechnology that aims to improve the treatment or diagnosis of a disease. In fact, one of the most important aspects of nanomedicine is to generate drugs with different components whose functions at the nanoscale are different when they are linked to when they are not. This makes the nanomedicines per se have a series of attributions that make, in general, their present use very clear advantages for the treatment with respect to conventional medicines. They are much more effective medicines, focussed on the target cells that are intended to be treated and with many less toxic effects.

For some editions Expoquímia has hosted conferences on this new type of medicine.

Numerous clinical trials are now underway in which the therapeutic efficacy of many nanomedicines is already being tested. Therefore, it is a fast-moving science that is already present in the market. Thus, there are already anti-tumor drugs that are nanomedicines, which have displaced the conventional treatment that was used until recently, for example, in breast cancer. And there are many more that we hope will get into the usual clinical practice in the coming years.

What types of diseases can nanomedicine be applied to? And with what results?

In principle, there is not a single specific prototype of disease in which nanomedicine can be applied or not. Any disease is susceptible of being treated by means of nanomedicine if  it is necessary to transport a drug of a specific form to a specific site, reducing the general undesirable effects of medicines  and  increasing their effectiveness. At the moment, it has been tested that the use of nanomedicines implies a greater therapeutic efficiency to be able to transport more drugs to the places where they are needed and much less to the places to which they should not arrive.

In reality, nanomedicines are drugs that have a specific transport system that makes that medicine instead of circulating freely through the blood is transported in a specific way to a specific site. During that transport, that drug can not act anywhere and, therefore, can not have any kind of adverse effect as if it were for free. And, in this sense, the results are good, as there is more therapeutic indication and much less general toxicity. Thus, in treatments such as cancer, where the drugs are very aggressive and have many adverse effects, nanomedicines compensate in a substantial way.

Do you think that a greater implantation of nanomedicine could eradicate diseases that, today, are incurable?

A disease is incurable because it has no known treatment or because that treatment is not specific enough or has a very narrow efficacy and toxicity index. That is, the therapeutic window is very narrow and per se they are very toxic. In that sense, nanomedicine, by reducing the general toxicity of the drug and being much more specific, can make certain diseases, which today have a low cure rate, improve. But nanomedicine is a specific chemical transport system, which always needs a drug or a molecule, which is the active principle that is, through a mechanism of action determined, to cure that disease. This includes gene therapy.

How can a major use of nanomedicine be encouraged? Is it open to public-private collaboration?

Definitely. Nanomedicines are just new medicines. Therefore, a drug that is effective, based on scientific evidence and medical at the level of clinical practice, will always have a majority use. Consequently, as in any other medicine, public-private collaboration is more than necessary because the amount of investment required to put a nanomedicine in the market is as high as that needed by any other medicine on the market. And today, such partnerships are essential to ensure that these drugs come to term.

Besides the economic aspect, are there other factors that can prevent the expansion of nanomedicine as a treatment?

Like any other medicine, the main problem that nanomedicine has is the high economic cost of its development. It must be borne in mind that it has to go through numerous regulatory phases, demonstrate efficacy and declare that there is no toxicity or an acceptable general toxicity like any other drug. And there the economic aspect is fundamental. In principle, there are no other factors. But it is true that, today, the production process of these nanomedicines is more complicated, since they are formed by several components. And there is no factory that is capable of generating any nanomedicine anywhere. And that is a problem, but at the same time, it represents an opportunity for the pharmaceutical industry.

In this sense, what is the purpose of the Nanomedicine Day that will take place in Expoquimia 2017?

The main objective is to disseminate what nanomedicine represents and means, as well as the therapeutic opportunities it entails,to facilitate the understanding  of the difference between a conventional medicine and a nanomedicine, how nanomedicines work and why they are more effective and less toxic and why there is so much interest in developing and using these systems to improve the results of current treatments.

Lastly, shall nanomedicine be the medicine of the 21st century?

Undoubtedly, many diseases will be treated with nanomedicines, since they allow a more effective treatment and with less toxicity.

 

By Eduard Pérez Moya

Read More

2nd SUMMER SCHOOL OF EUROPEAN AND INTERNATIONAL SOCIETIES FOR NANOMEDICINE (ESNAM/ISNM)

The ESNAM / ISNM Summer School is co-organized by ESNAM and CIBER-BBN (led by Simó Schwartz, president of ESNAN and transfer manager of CIBER-BBN as well as Scientific Director of Unit 20 of NANBIOSIS).

The summer school is aimed at any student or professional interested in nanomedicine. It will count on the presence of speakers of recognized prestige in the area, among which are the Scientific Directors and Coordinators of several of the units of NANBIOSIS.

The ESNAM / ISNM Summer School will be held on 28-29 September 2017 at the Hospital Vall d’Hebron, Barcelona

The registration deadline with accommodation included ends on June 30

Program and registration details

Read More